The Agency for Healthcare Research and Quality recently said that the evidence is insufficient to answer that question, though it didnt look at people taking GLP-1 drugs
Oncotarget 8 , 4927549292 (2017)
Nothing is really off limits, and I'm comfortable asking if I suspect a patient is using recreational drugs," Dr
63.Temizsoy E, Uysal G, Karadag N
Third, although our study provides valuable insights into the costs associated with GLP-1 RA use, future studies focused specifically on health care resource utilization may further improve our understanding of the sources and dynamics of the cost outcomes presented herein
Functional recovery ultimately most important outcome though must balance testing against re-injury risk